Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 2
Panelists discuss how data from the PERSEUS trial supports the use of daratumumab in quadruplet regimens to improve sustained minimal residual disease negativity and progression-free survival in transplant-eligible myeloma patients.
The PERSEUS Trial and Impact of MRD Negativity
The PERSEUS trial data reinforced the value of incorporating daratumumab into frontline therapy, especially in enhancing sustained minimal residual disease (MRD) negativity. MRD negativity, particularly sustained beyond 12 or 24 months, correlates strongly with improved progression-free and overall survival in transplant-eligible multiple myeloma patients.
The addition of daratumumab not only deepened responses but also showed marked benefit in functional high-risk patients—those who progress early despite standard therapy. These findings suggest that monoclonal antibody-based quadruplets may mitigate early disease failure in this challenging subgroup.
Furthermore, a head-to-head comparison of carfilzomib-based regimens raises the question of proteasome inhibitor choice. Carfilzomib shows promising MRD negativity rates and tolerability advantages in patients at risk for peripheral neuropathy, indicating a growing role in induction regimens for selected patients.